Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines
Open Access
- 1 January 2018
- journal article
- research article
- Published by Informa UK Limited in Clinical Ophthalmology
- Vol. 12, 811-+
- https://doi.org/10.2147/OPTH.S163451
Abstract
Purpose: The aim of this study was to determine whether somatotype influences the risk of hydroxychloroquine (HC) retinopathy (HCR) and whether dosing by real body weight (RBW), ideal body weight (IBW), or the lesser of these better predicts the risk of HCR. Patients and methods: A total of 565 patients taking HC for whom height and weight were recorded and a sensitive ancillary testing modality was used including 10-2 visual fields, spectral domain optical coherence tomography, fundus autofluorescence imaging, and multifocal electroretinography were enrolled. Body mass index (BMI) was compared for patients without and with HCR. Logistic regression models of age, cumulative dose, and daily dosing based on RBW, IBW, or lesser of these were compared. Area under the curve (AUC) of receiver operating characteristic plots was used to assess the diagnostic accuracy of RBW, IBW, and lesser of these guidelines for safe dosing. Probability plots for the risk of retinopathy versus BMI were compared for the different recommended guidelines on safe dosing. Results: A total of 41 patients had HCR. The median BMI was 27.6 (interquartile range [IQR] 24.3, 32.6) and 24.0 (IQR 21.0, 31.6) for patients without and with HCR (P=0.0102), respectively. AUC for univariate receiver operating characteristic plots of retinopathy versus dosing by RBW, IBW, and lesser of these was 0.71, 0.72, and 0.76, respectively. AUC for multivariate receiver operating characteristic plots of retinopathy versus models incorporating gender, age, cumulative dose, and BMI and differing by including dosing by RBW, IBW, and lesser of these was 0.82, 0.82, and 0.83, respectively. For all of the multivariate logistic models, the risk of retinopathy was higher for lower BMIs. Conclusion: Short, asthenic women are at higher risk for HCR. The 2011 American Academy of Ophthalmology (AAO) guidelines are safer for short, obese women. The 2016 AAO guidelines are safer for short, asthenic patients. Choosing daily dosing based on the lesser of the RBW and IBW guidelines is safer for all patients.Keywords
This publication has 12 references indexed in Scilit:
- Solving the Hydroxychloroquine Dosing Dilemma With a Smartphone AppJAMA Ophthalmology, 2018
- Adherence to Hydroxychloroquine Dosing Guidelines by RheumatologistsOphthalmology, 2017
- Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)Ophthalmology, 2016
- Hydroxychloroquine Screening Practice Patterns Within a Large Multispecialty Ophthalmic PracticeAmerican Journal of Ophthalmology, 2015
- The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine TherapyJAMA Ophthalmology, 2014
- The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in womenClinical Ophthalmology, 2014
- Impact of the Revised American Academy of Ophthalmology Guidelines Regarding Hydroxychloroquine Screening on Actual PracticeAmerican Journal of Ophthalmology, 2013
- Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine RetinopathyOphthalmology, 2011
- Mean body weight, height, and body mass index, United States 1960-2002.2004
- Animal toxicity and pharmacokinetics of hydroxychloroquine sulfateAmerican Journal Of Medicine, 1983